

Intraoral Photobiomodulation Therapy to Prevent Oral Mucositis in Patients Undergoing Hematopoietic Cell Transplantation

NCT05335434

Status	RECRUITING
Phase	Not Applicable
Sponsor	Dana-Farber Cancer Institute
Enrollment	20 participants

Key Eligibility Criteria

Inclusion (3)

- Planned to undergo myeloablative allogeneic HCT using FluBu4 conditioning and Tac-Mtx GVHD prophylaxis.
- Age ≥18 years.
- Ability to understand and the willingness to sign a written informed consent document.

Exclusion (4)

- Participants who have had treatment with intraoral PBMT within four weeks of admission for HSCT.
- Participants who have a history of radiation therapy to the head and neck.
- Participants who have a history of photosensitivity or underlying disease with known photosensitivity.
- Participants who are planned to receive palifermin for OM prevention.

Locations (1 total)

Brigham and Women's Hospital, Boston, Massachusetts, United States